Loading
Use the cancer registry itself as the trial machine: randomise patients at diagnosis, then let the registry collect the outcomes for a fraction of the usual cost.
Registry-based randomised trials (R-RCTs), pioneered in Swedish cardiology, use the registry for identification, randomisation and outcome follow-up. Oncology has the registries (Nordic, England, Netherlands) but almost no R-RCTs. The proposal funds a programme of five R-RCTs on high-value comparative questions with routine endpoints (surveillance intervals, adjuvant duration, supportive care) and develops the ethics and consent templates to make the design routine.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries, Trial design, endpoints and cost.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Karolinska University Hospital, Real-world evidence, Weak real-world evidence and registries, Trials enrol too few, too slowly.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Trials enrol too few, too slowly, Trial design, endpoints and cost.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.